[Skip to Navigation]
Research Letter
January 6, 2021

Mucocutaneous Adverse Events Associated With Oral Sirolimus for the Treatment of Vascular Anomalies

Author Affiliations
  • 1Department of Dermatology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Vascular Anomalies Center, Boston Children’s Hospital, Boston, Massachusetts
  • 3University of Massachusetts Medical School, Boston
  • 4Boston Children’s Hospital, Division of Hematology/Oncology, Harvard Medical School, Boston, Massachusetts
  • 5Complex Vascular Anomalies Program, Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
JAMA Dermatol. 2021;157(2):233-235. doi:10.1001/jamadermatol.2020.5180
Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words